BDSI buys US rights to BEMA (bioerodible mucoadhesive disc) drug tech
This article was originally published in Clinica
BioDelivery Sciences International (BDSI) has acquired the US rights to the BEMA (bioerodible mucoadhesive disc) drug delivery technology developed by biopharmaceutical company QLT for $3m. BDSI has also agreed to pay QLT up to $4m for achieving certain milestones, one of these being the NDA approval of BDSI's first BEMA product.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.